Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 EP39 | DOI: 10.1530/endoabs.63.EP39

1Universidad Europea de Madrid, Madrid, Spain; 2MSD, Madrid, Spain; 3Chief Department Endocrinology and Clinical Nutrition, Quiron Hospital, Madrid, Spain; 4Chief Department of Obstetrics & Gynaecology, Quiron Hospital, Madrid, Spain.


The adult female life could be divided into three broad phases: reproductive, perimenopause and postmenopause. The perimenopause starts 2 years before last bleeding and the postmenopause begins 12 months after amenorrhea (Harlow SD y Group 2012). Cardiovascular disease is the main cause of mortality in postmenopausal women and the factors that increase cardiovascular risk are well known but there is no evidence of relationship between menopause and cardiometabolic changes. Some results show metabolic variations during menopause in Chinese women but Spanish data are insufficient to determine an association between metabolic changes and menopausal transition. The main objective of this study was to evaluate the changes at the lipid profile in women that are in transition from perimenopause to postmenopause. This is a retrospective observational study of women who visited the Gynaecologist at Quiron hospital in Madrid from 2007–2018 years to consult about menopause or menopausal symptoms. Women were included if they had at least one analytic report with glucose and lipid profile (total cholesterol [TC], cholesterol-Low Density Lipoprotein [c-LDL], cholesterol-High Density Lipoprotein [c-HDL] and triglycerides [TG]) data. The information was collected anonymized from the hospital database. Women were classified according their last bleeding day on perimenopausal or postmenopausal following the 2011 Stages of Reproductive Aging Workshop. 275 women were included in the study; 242 postmenopausal and 33 perimenopausal. The menopause was natural on 85.95% and the median age of menopause was 50.0 years old (IQR=5.0) When analysing cardiovascular risk factors, 24.26% were smokers, 4.00% were diabetic, 14.55% had hypertension and 23.27% presented dyslipidaemia. Regarding the treatments 4.73% were receiving an antidiabetic, 20.73% a lipid lowering therapy, 13.82% an antihypertensive and 15.64% an antiosteoporotic drug. At the moment of the analytic report women were 55±13.0 years old; 1,731 (82%) reports were from postmenopausal women and 381 (18%) from perimenopausal with a mean of 7.68 reports/women. When comparing lipid profile, postmenopausal women had a significant lower c-HDL (67 mg/dl vs 62 mg/dl; P-value < 0.001) and a significant higher c-LDL (118.6 mg/dl vs 133.9 mg/dl; p-value < 0.001); TC (204.1 mg/dl vs 215.5 mg/dl, P value < 0.001) and TG (74 mg/dl vs 87 mg/dl; P-value < 0.001). These preliminary results showed that there exists a change on lipid profile during the menopausal transition.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts